Efficacy and safety of semaglutide once-weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with type 2 diabetes

Trial Profile

Efficacy and safety of semaglutide once-weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with type 2 diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SUSTAIN 5
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 12 Oct 2017 Results of a post hoc analysis of SUSTAIN 2-5 trials presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 15 Sep 2017 Results evaluating superiority of semaglutide in improvement of glycaemic control across SUSTAIN 1-5 clinical trials presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 15 Sep 2017 Results assessing the effect of once-weekly s.c. semaglutide onfasting plasma glucose (FPG) and postprandial glucose (PPG) levels across the SUSTAIN 1-5 trials presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top